LPGAT1 is a lysophospholipid acyltransferase localized to the endoplasmic reticulum that catalyzes fatty acyl chain remodeling of glycerophospholipids 1. The enzyme selectively transfers saturated long-chain fatty acids from acyl-CoA to lysophosphatidylglycerol (LPG) and lysophosphatidylethanolamine (LPE), with preference for stearoyl-CoA, thereby controlling phospholipid composition and supporting de novo hepatic lipid synthesis 2. LPGAT1-mediated phosphatidylglycerol (PG) remodeling is coupled with mitochondrial transport through interaction with the prohibitin/TIMM14 complex, enabling proper delivery of mature PG to mitochondria for cristae structure and cardiolipin synthesis 3. Loss of LPGAT1 function causes MEGDEL syndrome, characterized by fatty liver disease, 3-methylglutaconic aciduria, deafness, encephalopathy, dilated cardiomyopathy, and premature death, attributable to impaired mitochondrial structure and respiration 3. In zebrafish, Lpgat1 downregulation results in male infertility with reduced sperm motility and abnormal morphology, alongside severe embryonic developmental defects 4. LPGAT1 variants are associated with obesity in Native Americans, influencing BMI and percent body fat 5. Additionally, LPGAT1 upregulation promotes lung adenocarcinoma proliferation and is associated with unfavorable prognosis 6.